Heart disease remains the leading cause of death in the United States, and the risk climbs sharply after age 50. Excess weight — particularly the visceral fat that accumulates around the abdomen and internal organs — is one of the most powerful accelerants of cardiovascular risk. Over the past several years, a series of large clinical trials have established that GLP-1 receptor agonists do not just reduce body weight: they directly protect the heart, kidneys, and blood vessels in ways that go far beyond the number on the scale. If you are over 50 and managing weight, understanding these trials is not academic — it could meaningfully change your health trajectory.
Why Cardiovascular Risk Is Different After 50
Before age 50, the body has considerable metabolic resilience. After 50, several things shift simultaneously. Visceral fat accumulation increases, even without major weight gain. Arterial stiffness progresses. The kidneys begin to lose some filtering capacity. The heart’s electrical system becomes more vulnerable to rhythm disturbances. And chronic low-grade inflammation — driven partly by excess fat tissue and partly by the aging process itself — begins to accelerate damage across multiple organ systems.
Obesity does not cause cardiovascular disease in isolation, but it intensifies nearly every risk factor: high blood pressure, insulin resistance, abnormal cholesterol, systemic inflammation, and sleep apnea all worsen with excess weight. Treating obesity, therefore, is not cosmetic medicine — it is preventive cardiology.
The SELECT Trial: 20% Fewer Heart Attacks and Strokes
The most important cardiovascular trial for GLP-1 medications in non-diabetic patients is SELECT — the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity trial. Published in the New England Journal of Medicine in November 2023, it enrolled 17,604 adults who had established cardiovascular disease and a body mass index of 27 or higher, but who did not have type 2 diabetes.
Over a mean follow-up of nearly 40 months, participants receiving once-weekly semaglutide 2.4 mg experienced a 20% reduction in major adverse cardiovascular events — the composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke — compared with placebo (hazard ratio 0.80; 95% confidence interval 0.72–0.90; p < 0.001). That translates to 6.5% of the semaglutide group versus 8.0% of the placebo group experiencing one of these events.
Several aspects of this result deserve attention:
- The benefit appeared in people without diabetes, meaning glucose lowering alone cannot explain it.
- The benefit held up even though nearly all participants were already taking statins — drugs well established to reduce cardiovascular risk.
- Patients with heart failure — both with reduced and preserved ejection fraction — showed consistent benefit, with hazard ratios of 0.65 and 0.69 respectively.
- The heart failure composite outcome (cardiovascular death or HF hospitalization) was reduced by 18% (HR 0.82; 95% CI 0.71–0.96).
SELECT established GLP-1 receptor agonists as a legitimate cardiovascular therapy, not just a weight loss drug with cardiac side benefits.
The FLOW Trial: Protecting Your Kidneys Too
Kidney disease and heart disease are deeply intertwined. Damaged kidneys raise blood pressure, accumulate inflammatory toxins, and independently increase cardiovascular risk. For adults with type 2 diabetes — a population already at elevated cardiac risk — chronic kidney disease (CKD) is common and progressive.
The FLOW trial, published in the New England Journal of Medicine in 2024, enrolled 3,533 patients with type 2 diabetes and CKD. After a median follow-up of 3.4 years, semaglutide reduced the primary composite kidney outcome by 24% (HR 0.76; 95% CI 0.66–0.88; p = 0.0003). This composite included kidney failure onset, a sustained 50% or greater decline in kidney filtration rate, and death from kidney or cardiovascular causes.
Crucially, semaglutide also reduced all-cause mortality by 20% (HR 0.80; 95% CI 0.67–0.95) and cardiovascular mortality by 29% in this population. The kidney benefit was consistent across a wide range of CKD severity, including patients with eGFR as low as 25 mL/min/1.73 m². The number needed to treat to prevent one primary outcome event at three years was just 45 — a strong result for preventive cardiology.
For people over 50 with diabetes and any degree of kidney dysfunction, the FLOW data represent a strong argument for GLP-1 therapy as part of their standard care.
The SUMMIT Trial: Tirzepatide for Heart Failure
Heart failure with preserved ejection fraction (HFpEF) is sometimes called the obesity heart failure. The heart squeezes normally, but it has become stiff — largely from fat infiltration and chronic inflammation — and cannot relax properly to fill with blood. It affects millions of Americans over 60 and until recently had very limited treatment options.
The SUMMIT trial, published in the New England Journal of Medicine in early 2025, tested tirzepatide (the dual GIP/GLP-1 receptor agonist) in 731 patients with HFpEF and obesity. The primary composite outcome — cardiovascular death or worsening heart failure event — occurred in just 9.9% of the tirzepatide group versus 15.3% of the placebo group, a 38% risk reduction (HR 0.62; 95% CI 0.41–0.95; p = 0.026).
Worsening heart failure events alone fell by 46% in the tirzepatide group. Quality-of-life scores, measured by the Kansas City Cardiomyopathy Questionnaire, improved significantly more in the tirzepatide arm — a difference of 6.9 points, which exceeds the threshold for clinically meaningful benefit. For a condition that profoundly limits daily activity and independence, this quality-of-life improvement is arguably as important as the hard outcome data.
Atrial Fibrillation: A Newer and Surprising Finding
Atrial fibrillation (AF) is the most common cardiac rhythm disorder, affecting roughly 3–6 million Americans, with prevalence rising sharply after age 65. It substantially increases the risk of stroke and heart failure. Until recently, the relationship between GLP-1 drugs and AF risk was unclear.
At the Heart Rhythm 2026 meeting, researchers from the University of Virginia presented data from a study of over 13,000 patients showing that GLP-1 receptor agonists were associated with a significantly reduced risk of new-onset AF, even after accounting for weight loss. This was a remarkable finding: patients who lost 10% or more of their body weight, those who lost less than 10%, and even those who gained weight while taking GLP-1 medications all showed a reduced risk of AF compared with matched controls. The AF risk reduction was not driven by weight loss alone.
Patients over 65 showed what the researchers called a “remarkable” reduction in AF risk of approximately 44%. The leading hypothesis for this weight-independent benefit is that GLP-1 drugs reduce inflammation in the epicardial fat — the fat tissue surrounding the heart — which is a known driver of atrial arrhythmias. Semaglutide showed the strongest association with AF risk reduction among all the drugs studied.
How Do GLP-1 Drugs Protect the Heart?
The mechanisms underlying cardiovascular protection from GLP-1 drugs appear to be multiple and overlapping:
- Reduced visceral and epicardial fat: Fat around the heart and abdominal organs secretes inflammatory signals that damage blood vessels and trigger arrhythmias. GLP-1 drugs preferentially reduce this dangerous fat depot.
- Lower blood pressure: In the FLOW trial, semaglutide reduced systolic blood pressure by approximately 2.2 mmHg — modest but meaningful over years of treatment.
- Improved endothelial function: GLP-1 receptors on blood vessel walls promote vascular health and reduce arterial stiffness.
- Anti-inflammatory effects: Reduction in TNF-α, IL-6, and hs-CRP (by approximately 30% in some studies) lowers the inflammatory burden that accelerates atherosclerosis.
- Favorable cardiac remodeling: Tirzepatide reduced left ventricular mass in heart failure patients in the SUMMIT trial, reversing some of the structural changes that make the heart less efficient.
- Better metabolic signaling: Improved insulin sensitivity and glucose control reduce the glycation of proteins and the oxidative stress that damage blood vessels over time.
What This Means If You Are Over 50 in Savannah, Pooler, or Hinesville
If you are over 50, carrying excess weight, and have any cardiovascular risk factors — high blood pressure, elevated cholesterol, prediabetes or diabetes, kidney disease, or a history of heart problems — the evidence from SELECT, FLOW, SUMMIT, and the AF data collectively make a compelling case for discussing GLP-1 medications with your physician.
These are not drugs to take lightly. They have real side effects, require ongoing medical supervision, and must be part of a comprehensive approach that includes nutrition, physical activity, and lifestyle management. But the evidence of benefit is now among the strongest in preventive cardiology for any medication class introduced in the past decade.
Learn about medically supervised weight loss at Scale Solutions, where Dr. Donald L. Gates, MD, brings over 25 years of bariatric medicine experience to individualized treatment plans in Savannah, Pooler, and Hinesville, Georgia. You can also stay current with the latest GLP-1 research updates on our news page.
Monitoring and Safety Considerations
Starting a GLP-1 medication requires baseline evaluation of kidney function, heart health, thyroid history (a relative contraindication in some cases), and a review of current medications for interactions. Regular follow-up appointments allow monitoring of weight, blood pressure, kidney labs, and side effect management. The most common side effects — nausea, vomiting, constipation, and diarrhea — typically diminish with time and careful dose titration.
For patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2), GLP-1 receptor agonists are contraindicated. Pancreatitis has been reported as a rare adverse event and should be evaluated if severe abdominal pain develops. These are reasons why these medications should always be managed by a qualified physician, not obtained through unsupervised online platforms.
Ready to take the next step? Dr. Gates and the team at Scale Solutions can help you understand whether a GLP-1 program makes sense for your cardiovascular health profile. Call (912) 352-7546 or email info@scale-solutions.com. Visit Dr. Gates’ profile to learn more about his background and approach.
Medical Disclaimer: This article is intended for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. The research summarized here reflects findings from published clinical trials and peer-reviewed literature; individual results vary. GLP-1 medications are prescription drugs with potential side effects and contraindications. Always consult a qualified, licensed physician before starting, stopping, or changing any medication or treatment plan.
Frequently Asked Questions
What did the SELECT trial find about semaglutide and heart disease?
The SELECT trial, published in the New England Journal of Medicine in 2023, enrolled 17,604 adults with obesity and established cardiovascular disease but no diabetes. Semaglutide 2.4 mg weekly reduced the risk of major adverse cardiovascular events — heart attack, stroke, and cardiovascular death — by 20% (hazard ratio 0.80) compared with placebo over a mean follow-up of nearly 40 months. This benefit occurred on top of standard cardiovascular care including widespread statin use.
Can GLP-1 drugs help protect kidney function?
Yes. The FLOW trial found that semaglutide reduced serious kidney outcomes by 24% in patients with type 2 diabetes and chronic kidney disease over a median of 3.4 years. All-cause mortality fell by 20% and cardiovascular mortality by 29% in the same population. The benefit was consistent across patients with a wide range of kidney function severity.
What is HFpEF and how did tirzepatide help in the SUMMIT trial?
HFpEF stands for heart failure with preserved ejection fraction, a condition where the heart becomes stiff and cannot relax properly to fill with blood. It is closely linked to obesity and aging. In the SUMMIT trial, tirzepatide reduced the combined risk of cardiovascular death or worsening heart failure by 38% compared with placebo, and meaningfully improved quality-of-life scores in 731 patients with HFpEF and obesity.
Do GLP-1 drugs reduce atrial fibrillation risk?
Data presented at the Heart Rhythm 2026 meeting from a study of over 13,000 patients found that GLP-1 receptor agonists were associated with significantly lower rates of new-onset atrial fibrillation, even among patients who did not lose weight on the medication. Adults over 65 showed a particularly strong reduction of approximately 44%. Researchers believe the benefit may relate to reduced inflammation in the fat tissue surrounding the heart.
Do I need to have diabetes to benefit from GLP-1 heart protection?
No. The SELECT trial specifically enrolled patients without diabetes and still found a 20% reduction in major cardiovascular events. The cardiovascular benefits appear to operate through mechanisms beyond glucose lowering — including anti-inflammatory effects, visceral fat reduction, blood pressure lowering, and improved vascular function. Whether you have diabetes, prediabetes, or neither, the cardiovascular evidence is relevant if you have excess weight and cardiovascular risk factors.